133 related articles for article (PubMed ID: 33216547)
1. Optimization of the
Quancard J; Simic O; Pissot Soldermann C; Aichholz R; Blatter M; Renatus M; Erbel P; Melkko S; Endres R; Sorge M; Kieffer L; Wagner T; Beltz K; Mcsheehy P; Wartmann M; Régnier CH; Calzascia T; Radimerski T; Bigaud M; Weiss A; Bornancin F; Schlapbach A
J Med Chem; 2020 Dec; 63(23):14594-14608. PubMed ID: 33216547
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent, Highly Selective, and
Pissot Soldermann C; Simic O; Renatus M; Erbel P; Melkko S; Wartmann M; Bigaud M; Weiss A; McSheehy P; Endres R; Santos P; Blank J; Schuffenhauer A; Bold G; Buschmann N; Zoller T; Altmann E; Manley PW; Dix I; Buchdunger E; Scesa J; Quancard J; Schlapbach A; Bornancin F; Radimerski T; Régnier CH
J Med Chem; 2020 Dec; 63(23):14576-14593. PubMed ID: 33252239
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
Lu T; Connolly PJ; Philippar U; Sun W; Cummings MD; Barbay K; Gys L; Van Nuffel L; Austin N; Bekkers M; Shen F; Cai A; Attar R; Meerpoel L; Edwards J
Bioorg Med Chem Lett; 2019 Dec; 29(23):126743. PubMed ID: 31678006
[TBL] [Abstract][Full Text] [Related]
4. N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
Schlapbach A; Revesz L; Pissot Soldermann C; Zoller T; Régnier CH; Bornancin F; Radimerski T; Blank J; Schuffenhauer A; Renatus M; Erbel P; Melkko S; Heng R; Simic O; Endres R; Wartmann M; Quancard J
Bioorg Med Chem Lett; 2018 Jul; 28(12):2153-2158. PubMed ID: 29759726
[TBL] [Abstract][Full Text] [Related]
5. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
6. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
[TBL] [Abstract][Full Text] [Related]
8. Peptide-based covalent inhibitors of MALT1 paracaspase.
Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
Asaba KN; Adachi Y; Tokumaru K; Watanabe A; Goto Y; Aoki T
Bioorg Med Chem Lett; 2021 Jun; 41():127996. PubMed ID: 33775836
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.
Richard DJ; Verheijen JC; Curran K; Kaplan J; Toral-Barza L; Hollander I; Lucas J; Yu K; Zask A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6830-5. PubMed ID: 19896845
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
13.
Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
15. Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
Liu KL; Li XY; Wang DP; Xue WH; Qian XH; Li YH; Lin QQ; Li S; Meng FH
J Med Chem; 2021 Sep; 64(18):13356-13372. PubMed ID: 34473510
[TBL] [Abstract][Full Text] [Related]
16. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
17. A patent review of MALT1 inhibitors (2013-present).
Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
[TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
[TBL] [Abstract][Full Text] [Related]
19. Development of new Malt1 inhibitors and probes.
Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
[TBL] [Abstract][Full Text] [Related]
20. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
